Blood-Induced Arthropathy in Hemophilia: Mechanisms and Heterogeneity

Seminars in Thrombosis and Hemostasis

Volumn 41, Issue 8, 2015, Pages 832-837

  Blobel, Carl P ^a,b,c   Haxaire, Coline ^a   Kalliolias, George D ^a,b   Dicarlo, Edward ^a   Salmon, Jane ^a,b   Srivastava, Alok ^d  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

cartilage degradation; hemophilic arthropathy; inflammation; osteoarthritis; rheumatoid arthritis

Indexed keywords

ARTHROPATHY; ARTICLE; GENETIC HETEROGENEITY; HEMOPHILIC ARTHROPATHY; HUMAN; INFLAMMATORY ARTHROPATHY; KNOWLEDGE; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; ARTHRITIS, RHEUMATOID; COMPLICATION; HEMOPHILIA A; PATHOLOGY;

ARTHRITIS, RHEUMATOID; HEMOPHILIA A; HUMANS; OSTEOARTHRITIS;

EID: 84946722349     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0035-1564445     Document Type: Article

References (61)

1. Simpson M. L.; Valentino L. A. Management of joint bleeding in hemophilia. Expert Rev Hematol: 2012; 5 4 459 468
2. Stephensen D.; Rodriguez-Merchan E. C. Orthopaedic co-morbidities in the elderly haemophilia population: a review. Haemophilia: 2013; 19 2 166 173
3. Rodriguez-Merchan E. C. Prevention of the musculoskeletal complications of hemophilia. Adv Prev Med: 2012;; doi: 10.1155/2012/201271
4. Aznar J. A.; Marco A.; Jiménez-Yuste V.; et al. Spanish Haemophilia Epidemiological Study Working Group. Is on-demand treatment effective in patients with severe haemophilia? Haemophilia: 2012; 18 5 738 742
5. Khawaji M.; Astermark J.; Berntorp E. Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life. Eur J Haematol: 2012; 88 4 329 335
6. Manco-Johnson M. J.; Abshire T. C.; Shapiro A. D.; et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med: 2007; 357 6 535 544
7. Jayandharan G. R.; Srivastava A. The phenotypic heterogeneity of severe hemophilia. Semin Thromb Hemost: 2008; 34 1 128 141
8. Valentino L. A.; Hakobyan N.; Enockson C.; et al. Exploring the biological basis of haemophilic joint disease: experimental studies. Haemophilia: 2012; 18 3 310 318
9. Valentino L. A. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy. J Thromb Haemost: 2010; 8 9 1895 1902
10. Sen D.; Chapla A.; Walter N.; Daniel V.; Srivastava A.; Jayandharan G. R. Nuclear factor (NF)-κB and its associated pathways are major molecular regulators of blood-induced joint damage in a murine model of hemophilia. J Thromb Haemost: 2013; 11 2 293 306
11. Forsyth A. L.; Rivard G. E.; Valentino L. A.; et al. Consequences of intra-articular bleeding in haemophilia: science to clinical practice and beyond. Haemophilia: 2012; 18 04 112 119
12. Haxaire C.; Blobel C. P. With blood in the joint - what happens next? Could activation of a pro-inflammatory signalling axis leading to iRhom2/TNFα-convertase-dependent release of TNFα contribute to haemophilic arthropathy. Haemophilia: 2014; 20 04 11 14
13. Nieuwenhuizen L.; Roosendaal G.; Mastbergen S. C.; et al. Antiplasmin, but not amiloride, prevents synovitis and cartilage damage following hemarthrosis in hemophilic mice. J Thromb Haemost: 2014; 12 2 237 245
14. Melchiorre D.; Morfini M.; Linari S.; Zignego A. L.; Innocenti M.; Matucci Cerinic M. Anti-TNF-α therapy prevents the recurrence of joint bleeding in haemophilia and arthritis. Rheumatology (Oxford): 2014; 53 3 576 578
15. Narkbunnam N.; Sun J.; Hu G.; et al. IL-6 receptor antagonist as adjunctive therapy with clotting factor replacement to protect against bleeding-induced arthropathy in hemophilia. J Thromb Haemost: 2013; 11 5 881 893
16. van Meegeren M. E.; Roosendaal G.; Coeleveld K.; Nieuwenhuizen L.; Mastbergen S. C.; Lafeber F. P. A single intra-articular injection with IL-4 plus IL-10 ameliorates blood-induced cartilage degeneration in haemophilic mice. Br J Haematol: 2013; 160 4 515 520
17. Astermark J.; Dolan G.; Hilberg T.; et al. Managing haemophilia for life: 4th Haemophilia Global Summit. Haemophilia: 2014; 20 05 1 20
18. Cross S.; Vaidya S.; Fotiadis N. Hemophilic arthropathy: a review of imaging and staging. Semin Ultrasound CT MR: 2013; 34 6 516 524
19. Sierra Aisa C.; Lucía Cuesta J. F.; Rubio Martínez A.; et al. Comparison of ultrasound and magnetic resonance imaging for diagnosis and follow-up of joint lesions in patients with haemophilia. Haemophilia: 2014; 20 1 e51 e57
20. Martinoli C.; Della Casa Alberighi O.; Di Minno G.; et al. Development and definition of a simplified scanning procedure and scoring method for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US). Thromb Haemost: 2013; 109 6 1170 1179
21. Melchiorre D.; Linari S.; Innocenti M.; et al. Ultrasound detects joint damage and bleeding in haemophilic arthropathy: a proposal of a score. Haemophilia: 2011; 17 1 112 117
22. Doria A. S. State-of-the-art imaging techniques for the evaluation of haemophilic arthropathy: present and future. Haemophilia: 2010; 16 05 107 114
23. Lundin B.; Manco-Johnson M. L.; Ignas D. M.; et al. International Prophylaxis Study Group. An MRI scale for assessment of haemophilic arthropathy from the International Prophylaxis Study Group. Haemophilia: 2012; 18 6 962 970
24. Doria A. S.; Keshava S. N.; Mohanta A.; et al. Diagnostic accuracy of ultrasound for assessment of hemophilic arthropathy: MRI correlation. AJR Am J Roentgenol: 2015; 204 3 W336-47
25. Bottini N.; Firestein G. S. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat Rev Rheumatol: 2013; 9 1 24 33
26. Bartok B.; Firestein G. S. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev: 2010; 233 1 233 255
27. Firestein G. S. Evolving concepts of rheumatoid arthritis. Nature: 2003; 423 6937 356 361
28. Strand V.; Kimberly R.; Isaacs J. D. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov: 2007; 6 1 75 92
29. Feldmann M.; Maini S. R. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev: 2008; 223 7 19
30. Taylor P. C.; Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol: 2009; 5 10 578 582
31. Ovlisen K.; Kristensen A. T.; Jensen A. L.; Tranholm M. IL-1 beta, IL-6, KC and MCP-1 are elevated in synovial fluid from haemophilic mice with experimentally induced haemarthrosis. Haemophilia: 2009; 15 3 802 810
32. Jansen N. W.; Roosendaal G.; Hooiveld M. J.; et al. Interleukin-10 protects against blood-induced joint damage. Br J Haematol: 2008; 142 6 953 961
33. van Meegeren M. E.; Roosendaal G.; van Veghel K.; Mastbergen S. C.; Lafeber F. P. A short time window to profit from protection of blood-induced cartilage damage by IL-4 plus IL-10. Rheumatology (Oxford): 2013; 52 9 1563 1571
34. Rodriguez-Merchan E. C. Musculoskeletal complications of hemophilia. HSS J: 2010; 6 1 37 42
35. Lambert T.; Auerswald G.; Benson G.; et al. Joint disease, the hallmark of haemophilia: what issues and challenges remain despite the development of effective therapies? Thromb Res: 2014; 133 6 967 971
36. Rodriguez-Merchan E. C.; De la Corte-Rodriguez H.; Jimenez-Yuste V. Radiosynovectomy in haemophilia: long-term results of 500 procedures performed in a 38-year period. Thromb Res: 2014; 134 5 985 990
37. 90 citrate in haemophilic synovitis: Brazilian experience. Haemophilia: 2011; 17 1 e211 e216
38. Hakobyan N.; Enockson C.; Cole A. A.; Sumner D. R.; Valentino L. A. Experimental haemophilic arthropathy in a mouse model of a massive haemarthrosis: gross, radiological and histological changes. Haemophilia: 2008; 14 4 804 809
39. Valentino L. A.; Hakobyan N. Histological changes in murine haemophilic synovitis: a quantitative grading system to assess blood-induced synovitis. Haemophilia: 2006; 12 6 654 662
40. Felson D. T. Clinical practice. Osteoarthritis of the knee. N Engl J Med: 2006; 354 8 841 848
41. Fosang A. J.; Beier F. Emerging Frontiers in cartilage and chondrocyte biology. Best Pract Res Clin Rheumatol: 2011; 25 6 751 766
42. Chu C. R.; Millis M. B.; Olson S. A. Osteoarthritis: From Palliation to Prevention: AOA Critical Issues. J Bone Joint Surg Am: 2014; 96 15 e130
43. Kiapour A. M.; Murray M. M. Basic science of anterior cruciate ligament injury and repair. Bone Joint Res: 2014; 3 2 20 31
44. Olson S. A.; Horne P.; Furman B.; et al. The role of cytokines in posttraumatic arthritis. J Am Acad Orthop Surg: 2014; 22 1 29 37
45. Glasson S. S. In vivo osteoarthritis target validation utilizing genetically-modified mice. Curr Drug Targets: 2007; 8 2 367 376
46. Glasson S. S.; Askew R.; Sheppard B.; et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature: 2005; 434 7033 644 648
47. Glasson S. S.; Blanchet T. J.; Morris E. A. The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. Osteoarthritis Cartilage: 2007; 15 9 1061 1069
48. Ma H. L.; Blanchet T. J.; Peluso D.; Hopkins B.; Morris E. A.; Glasson S. S. Osteoarthritis severity is sex dependent in a surgical mouse model. Osteoarthritis Cartilage: 2007; 15 6 695 700
49. Little C. B.; Barai A.; Burkhardt D.; et al. Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development. Arthritis Rheum: 2009; 60 12 3723 3733
50. Stanton H.; Rogerson F. M.; East C. J.; et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature: 2005; 434 7033 648 652
51. Troeberg L.; Nagase H. Proteases involved in cartilage matrix degradation in osteoarthritis. Biochim Biophys Acta: 2012; 1824 1 133 145
52. Miller R. E.; Lu Y.; Tortorella M. D.; Malfait A. M. Genetically Engineered Mouse Models Reveal the Importance of Proteases as Osteoarthritis Drug Targets. Curr Rheumatol Rep: 2013; 15 8 350
53. Bayliss M. T.; Hutton S.; Hayward J.; Maciewicz R. A. Distribution of aggrecanase (ADAMts 4/5) cleavage products in normal and osteoarthritic human articular cartilage: the influence of age, topography and zone of tissue. Osteoarthritis Cartilage: 2001; 9 6 553 560
54. Little C. B.; Fosang A. J. Is cartilage matrix breakdown an appropriate therapeutic target in osteoarthritis-insights from studies of aggrecan and collagen proteolysis? Curr Drug Targets: 2010; 11 5 561 575
55. Fosang A. J.; Little C. B. Drug insight: aggrecanases as therapeutic targets for osteoarthritis. Nat Clin Pract Rheumatol: 2008; 4 8 420 427
56. Lafeber F. P.; van Spil W. E. Osteoarthritis year 2013 in review: biomarkers; reflecting before moving forward, one step at a time. Osteoarthritis Cartilage: 2013; 21 10 1452 1464
57. Conaghan P. G.; Kloppenburg M.; Schett G.; Bijlsma J. W.; EULAR osteoarthritis ad hoc committee. Osteoarthritis research priorities: a report from a EULAR ad hoc expert committee. Ann Rheum Dis: 2014; 73 8 1442 1445
58. Hunter D. J.; Nevitt M.; Losina E.; Kraus V. Biomarkers for osteoarthritis: current position and steps towards further validation. Best Pract Res Clin Rheumatol: 2014; 28 1 61 71
59. Lotz M.; Martel-Pelletier J.; Christiansen C.; et al. Value of biomarkers in osteoarthritis: current status and perspectives. Ann Rheum Dis: 2013; 72 11 1756 1763
60. Jansen N. W.; Roosendaal G.; Lundin B.; et al. The combination of the biomarkers urinary C-terminal telopeptide of type II collagen, serum cartilage oligomeric matrix protein, and serum chondroitin sulfate 846 reflects cartilage damage in hemophilic arthropathy. Arthritis Rheum: 2009; 60 1 290 298
61. van Vulpen L. F.; van Meegeren M. E.; Roosendaal G.; et al. Biochemical markers of joint tissue damage increase shortly after a joint bleed; an explorative human and canine in vivo study. Osteoarthritis Cartilage: 2015; 23 1 63 69